A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27
fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until
time of progression in patients with recurrent high grade gliomas (grade III and grade IV).
Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior
exposure to bevacizumab.